Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, announced Biogen Inc. (Nasdaq:BIIB) has exercised an option for an additional disease target in gene therapy as part of the companies’ ongoing research collaboration to develop and commercialize CRISPR-based medicines.
